32
Participants
Start Date
December 31, 2013
Primary Completion Date
April 30, 2016
Study Completion Date
August 31, 2016
Arm A: Rituximab
Rituximab 375 mg/m² IV x 4 weekly doses.
Arm B: GA101
GA101 1,000 mg (flat dose) IV x 4 weekly doses.
Montefiore Medical Center, The Bronx
Susquehanna Health Cancer Center, Williamsport
Geisinger Medical Center, Danville
Fox Chase Cancer Center, Philadelphia
Reading Hospital, West Reading
Greater Baltimore Medical Center, Baltimore
University of Virginia, Charlottesburg
Charleston Area Medical Center (CAMC), Charleston
St. Joseph's/Candler Health System, Savannah
University of South Alabama, Mobile
Toledo Community Oncology Program, Toledo
University Hospitals Case Medical Center, Cleveland
Aultman Hospital, Canton
Indiana University, Indianapolis
St. Joseph Mercy Health System, Ann Arbor
Siouxland Hematology Oncology Associates, Sioux City
ProHealth Care, Inc., Waukesha
Aurora Health Care, Wauwatosa
Dean Clinic, Madison
Gundersen Health System, La Crosse
Metro MN CCOP, Saint Louis Park
Mayo Clinic, Rochester
Carle Cancer Center, Urbana
Decatur Memorial Hospital, Decatur
Missouri Valley Cancer Consortium, Omaha
Ochsner Cancer Institute, New Orleans
Marin Cancer Care, Greenbrae
Tufts Medical Center, Boston
Collaborators (1)
Genentech, Inc.
INDUSTRY
PrECOG, LLC.
OTHER